Price$12.59-0.35 (-2.70%)
01:30 PM07:45 PM
News · 26 weeks55-80%
2025-10-262026-04-19
Mix3690d
- Insider14(39%)
- SEC Filings12(33%)
- Other8(22%)
- Earnings2(6%)
Latest news
25 items- SECSEC Form DEFA14A filed by NovoCure LimitedDEFA14A - NovoCure Ltd (0001645113) (Filer)
- SECSEC Form DEF 14A filed by NovoCure LimitedDEF 14A - NovoCure Ltd (0001645113) (Filer)
- SECNovoCure Limited filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - NovoCure Ltd (0001645113) (Filer)
- PRNovocure to Report First Quarter 2026 Financial ResultsNovocure (NASDAQ:NVCR) will report financial results for the first quarter 2026 on April 30, 2026, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, April 30, to discuss the company's financial results for the three-month period that ended March 31, 2026. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link. The slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure's website, www.novocure.com/invest
- SECAmendment: SEC Form SCHEDULE 13G/A filed by NovoCure LimitedSCHEDULE 13G/A - NovoCure Ltd (0001645113) (Subject)
- SECNovoCure Limited filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - NovoCure Ltd (0001645113) (Filer)
- PRNovocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic CancerNovocure (NASDAQ:NVCR) announced positive results today from the Phase 2 PANOVA-4 trial of Tumor Treating Fields (TTFields) therapy concomitant with atezolizumab (Tecentriq®), gemcitabine and nab-paclitaxel (gem/nab-pac) as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC). PANOVA-4 met its pre-specified primary endpoint, achieving a statistically significant improvement in disease control rate (DCR) compared to the DCR reported in the Phase 3 MPACT study used as the historical control.1 The DCR in patients treated with TTFields therapy concomitantly with atezolizumab and gem/nab-pac (N=78) was 74.4% compared to a DCR of 48% in patients receiving gem/nab-pac a
- INSIDERFormer Chief Medical Officer Leupin Nicolas sold $14,636 worth of Ordinary Shares (1,100 units at $13.31), decreasing direct ownership by 1% to 102,979 units (SEC Form 4)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERFormer Chief Executive Officer Cordova Ashley covered exercise/tax liability with 17,638 units of Ordinary Shares, decreasing direct ownership by 4% to 422,570 units (SEC Form 4)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERGeneral Counsel Ben Arye Barak was granted 50,125 units of Ordinary Shares, increasing direct ownership by 26% to 242,453 units (SEC Form 4)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERChf Medical and Innovation Ofr Weinberg Uri was granted 50,125 units of Ordinary Shares and sold $85,314 worth of Ordinary Shares (6,412 units at $13.31), increasing direct ownership by 20% to 267,190 units (SEC Form 4)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERChief Financial Officer Brackmann Christoph was granted 55,137 units of Ordinary Shares and sold $85,314 worth of Ordinary Shares (6,412 units at $13.31), increasing direct ownership by 36% to 182,842 units (SEC Form 4)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERChief Executive Officer Leonard Frank X sold $74,603 worth of Ordinary Shares (5,607 units at $13.31) and was granted 150,000 units of Ordinary Shares, increasing direct ownership by 41% to 493,793 units (SEC Form 4)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERChief Operating Officer Paravasthu Mukund was granted 45,112 units of Ordinary Shares and sold $667,214 worth of Ordinary Shares (48,623 units at $13.72), decreasing direct ownership by 5% to 72,832 units (SEC Form 4)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERChief Human Resources Officer Puri Michal Nath was granted 40,100 units of Ordinary Shares and sold $14,636 worth of Ordinary Shares (1,100 units at $13.31), increasing direct ownership by 24% to 201,322 units (SEC Form 4)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERExecutive Chairman Doyle William F was granted 400,284 units of Ordinary Shares and sold $932,883 worth of Ordinary Shares (71,887 units at $12.98) (SEC Form 4)4 - NovoCure Ltd (0001645113) (Issuer)
- SECSEC Form 144 filed by NovoCure Limited144 - NovoCure Ltd (0001645113) (Subject)
- SECSEC Form 144 filed by NovoCure Limited144 - NovoCure Ltd (0001645113) (Subject)
- INSIDERFormer Chief Executive Officer Cordova Ashley covered exercise/tax liability with 21,179 units of Ordinary Shares and was granted 23,818 units of Ordinary Shares, increasing direct ownership by 0.60% to 440,208 units (SEC Form 4)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERChief Human Resources Officer Puri Michal Nath sold $19,690 worth of Ordinary Shares (1,441 units at $13.66), decreasing direct ownership by 0.88% to 162,322 units (SEC Form 4)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERChief Executive Officer Leonard Frank X was granted 18,621 units of Ordinary Shares and sold $230,585 worth of Ordinary Shares (16,966 units at $13.59), increasing direct ownership by 0.48% to 349,400 units (SEC Form 4)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERGeneral Counsel Ben Arye Barak was granted 17,755 units of Ordinary Shares, increasing direct ownership by 10% to 192,328 units (SEC Form 4)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERChf Medical and Innovation Ofr Weinberg Uri sold $146,863 worth of Ordinary Shares (10,733 units at $13.68) and was granted 12,992 units of Ordinary Shares, increasing direct ownership by 1% to 223,477 units (SEC Form 4)4 - NovoCure Ltd (0001645113) (Issuer)
- PRNovocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung CancerNovocure to launch Optune Lua in Japan with national reimbursement coverage Novocure (NASDAQ:NVCR) announced today that Japan's Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua® through the country's National Health Insurance coverage. Optune Lua is approved in Japan for concurrent use with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced/recurrent NSCLC who progressed on or after platinum-based chemotherapy. "Lung cancer remains one of the leading causes of cancer deaths in Japan. Healthcare providers and people living with this disease have an urgent need for access to approved treatment options," said Hidehito Kotani, Vice President of
- PRNovocure to Participate in 2026 Leerink Global Healthcare ConferenceNovocure (NASDAQ:NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 10, 2026. Frank Leonard, Chief Executive Officer, and Christoph Brackmann, Chief Financial Officer, will take part in a fireside chat at 11:20 a.m. EST, as well as one-on-one meetings with investors throughout the event. A live audio webcast of this presentation can be accessed from the Investor Relations page of Novocure's website, www.novocure.com/investor-relations, and will be available for replay for at least 14 days following the event. About Novocure Novocure is a global oncology company working to extend survival in some of the most aggressive for